RU2712251C1 - Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения - Google Patents

Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения Download PDF

Info

Publication number
RU2712251C1
RU2712251C1 RU2018146031A RU2018146031A RU2712251C1 RU 2712251 C1 RU2712251 C1 RU 2712251C1 RU 2018146031 A RU2018146031 A RU 2018146031A RU 2018146031 A RU2018146031 A RU 2018146031A RU 2712251 C1 RU2712251 C1 RU 2712251C1
Authority
RU
Russia
Prior art keywords
antibody
cell
antibodies
amino acid
disease
Prior art date
Application number
RU2018146031A
Other languages
English (en)
Russian (ru)
Inventor
Ольга Владимировна Британова
Дмитрий Борисович Староверов
Анна Валентиновна Евстратьева
Алексей Константинович Мисорин
Тимофей Александрович Неманкин
Мария Александровна Щемелева
Анна Константиновна Владимирова
Арина Витальевна Аникина
Роман Алексеевич Иванов
Дмитрий Валентинович Морозов
Павел Андреевич Яковлев
Сергей Анатольевич Лукьянов
Original Assignee
Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) filed Critical Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России)
Priority to RU2018146031A priority Critical patent/RU2712251C1/ru
Priority to ARP190103840A priority patent/AR117734A1/es
Priority to PH1/2021/551775A priority patent/PH12021551775A1/en
Priority to PCT/RU2019/050258 priority patent/WO2020091635A2/ru
Priority to CN201980092905.7A priority patent/CN113646333B/zh
Priority to KR1020217023541A priority patent/KR102788029B1/ko
Priority to CA3127767A priority patent/CA3127767A1/en
Priority to TW108147432A priority patent/TWI917314B/zh
Application granted granted Critical
Publication of RU2712251C1 publication Critical patent/RU2712251C1/ru
Priority to JP2021537707A priority patent/JP2022532274A/ja
Priority to CA3124813A priority patent/CA3124813A1/en
Priority to PE2021001081A priority patent/PE20220217A1/es
Priority to CN202080016346.4A priority patent/CN114144432A/zh
Priority to CR20210354A priority patent/CR20210354A/es
Priority to MA53689A priority patent/MA53689B1/fr
Priority to US17/417,686 priority patent/US12227572B2/en
Priority to BR112021012555-8A priority patent/BR112021012555A2/pt
Priority to KR1020217023568A priority patent/KR20220131489A/ko
Priority to MX2021007719A priority patent/MX2021007719A/es
Priority to PCT/RU2020/050024 priority patent/WO2020139175A2/ru
Priority to EA202191813A priority patent/EA202191813A1/ru
Priority to SG11202106975VA priority patent/SG11202106975VA/en
Priority to MYPI2021003585A priority patent/MY205967A/en
Priority to AU2020204492A priority patent/AU2020204492A1/en
Priority to EP20734640.4A priority patent/EP3907239A4/en
Priority to CONC2021/0008218A priority patent/CO2021008218A2/es
Priority to ZA2021/04357A priority patent/ZA202104357B/en
Priority to ECSENADI202146333A priority patent/ECSP21046333A/es
Priority to JOJO/P/2021/0169A priority patent/JOP20210169B1/ar
Priority to CL2021001705A priority patent/CL2021001705A1/es
Priority to IL284370A priority patent/IL284370A/en
Priority to PH12021551532A priority patent/PH12021551532A1/en
Priority to CONC2021/0009689A priority patent/CO2021009689A2/es

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2018146031A 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения RU2712251C1 (ru)

Priority Applications (32)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
ARP190103840A AR117734A1 (es) 2018-12-25 2019-12-23 ANTICUERPOS HUMANIZADOS CONTRA LA REGIÓN DE LA CADENA b DE LA 9NA FAMILIA TRBV9 DEL TCR HUMANO, Y SUS MÉTODOS DE USO
PH1/2021/551775A PH12021551775A1 (en) 2018-12-25 2019-12-24 Monoclonal antibodies that specifically bind to the beta region of the TRBV-9 family of the human T-cell receptor, and methods for their use
PCT/RU2019/050258 WO2020091635A2 (ru) 2018-12-25 2019-12-24 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения
CN201980092905.7A CN113646333B (zh) 2018-12-25 2019-12-24 针对人TRBV9的β链区域的单克隆抗体
KR1020217023541A KR102788029B1 (ko) 2018-12-25 2019-12-24 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체
CA3127767A CA3127767A1 (en) 2018-12-25 2019-12-24 Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human t-cell receptor, and methods for their use
TW108147432A TWI917314B (zh) 2018-12-25 2019-12-24 針對人類ＴＣＲ ＴＲＢＶ９第９家族之β鏈區的人類化抗體及其使用方法
EP20734640.4A EP3907239A4 (en) 2018-12-25 2020-02-20 MONOCLONAL ANTIBODIES AGAINST THE BETA CHAIN REGION OF HUMAN TRBV9
MA53689A MA53689B1 (fr) 2018-12-25 2020-02-20 Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
EA202191813A EA202191813A1 (ru) 2018-12-25 2020-02-20 Моноклональные антитела против участка бета-цепи trbv9 человека
PE2021001081A PE20220217A1 (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
CN202080016346.4A CN114144432A (zh) 2018-12-25 2020-02-20 针对人TRBV9的β链区域的单克隆抗体
CR20210354A CR20210354A (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso
JP2021537707A JP2022532274A (ja) 2018-12-25 2020-02-20 ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体
US17/417,686 US12227572B2 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human TRBV9
BR112021012555-8A BR112021012555A2 (pt) 2018-12-25 2020-02-20 Anticorpos monoclonais contra a região de cadeia beta do trbv9 humano
KR1020217023568A KR20220131489A (ko) 2018-12-25 2020-02-20 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체
MX2021007719A MX2021007719A (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso.
PCT/RU2020/050024 WO2020139175A2 (ru) 2018-12-25 2020-02-20 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения
CA3124813A CA3124813A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
SG11202106975VA SG11202106975VA (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
MYPI2021003585A MY205967A (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
AU2020204492A AU2020204492A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human TRBV9
CONC2021/0008218A CO2021008218A2 (es) 2018-12-25 2021-06-23 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso
ZA2021/04357A ZA202104357B (en) 2018-12-25 2021-06-24 Monoclonal antibodies against the beta chain region of human trbv9
ECSENADI202146333A ECSP21046333A (es) 2018-12-25 2021-06-24 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano y sus métodos de uso
JOJO/P/2021/0169A JOP20210169B1 (ar) 2018-12-25 2021-06-24 أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
CL2021001705A CL2021001705A1 (es) 2018-12-25 2021-06-24 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso.
IL284370A IL284370A (en) 2018-12-25 2021-06-24 Monoclonal antibodies against the beta chain region of human TRBV9
PH12021551532A PH12021551532A1 (en) 2018-12-25 2021-06-25 Monoclonal antibodies against the beta chain region of human trbv9
CONC2021/0009689A CO2021009689A2 (es) 2018-12-25 2021-07-23 Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Publications (1)

Publication Number Publication Date
RU2712251C1 true RU2712251C1 (ru) 2020-01-27

Family

ID=69184123

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Country Status (25)

Country Link
US (1) US12227572B2 (https=)
EP (1) EP3907239A4 (https=)
JP (1) JP2022532274A (https=)
KR (2) KR102788029B1 (https=)
CN (2) CN113646333B (https=)
AR (1) AR117734A1 (https=)
AU (1) AU2020204492A1 (https=)
BR (1) BR112021012555A2 (https=)
CA (2) CA3127767A1 (https=)
CL (1) CL2021001705A1 (https=)
CO (2) CO2021008218A2 (https=)
CR (1) CR20210354A (https=)
EA (1) EA202191813A1 (https=)
EC (1) ECSP21046333A (https=)
IL (1) IL284370A (https=)
JO (1) JOP20210169B1 (https=)
MA (1) MA53689B1 (https=)
MX (1) MX2021007719A (https=)
MY (1) MY205967A (https=)
PE (1) PE20220217A1 (https=)
PH (2) PH12021551775A1 (https=)
RU (1) RU2712251C1 (https=)
SG (1) SG11202106975VA (https=)
WO (2) WO2020091635A2 (https=)
ZA (1) ZA202104357B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532274A (ja) * 2018-12-25 2022-07-14 ジョイント・ストック・カンパニー “バイオキャド” ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体
WO2023146437A1 (en) * 2022-01-31 2023-08-03 Joint Stock Company «Biocad» Pharmaceutical composition of anti-trbv9 antibody and use thereof
RU2826886C1 (ru) * 2022-01-31 2024-09-17 Акционерное общество "БИОКАД" Фармацевтическая композиция анти-trbv9 антитела и ее применение

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
WO2017137453A1 (en) * 2016-02-08 2017-08-17 Polybiocept Ab T-cell receptor sequences for active immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
WO2017137453A1 (en) * 2016-02-08 2017-08-17 Polybiocept Ab T-cell receptor sequences for active immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOYABE S et. al. "Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection", Clinical & Experimental Immunology, Vol. 135, Is. 1, October 2003, pp. 92-97, 08.09.2003. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532274A (ja) * 2018-12-25 2022-07-14 ジョイント・ストック・カンパニー “バイオキャド” ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体
US12227572B2 (en) 2018-12-25 2025-02-18 Joint Stock Company “Biocad” Monoclonal antibodies against the beta chain region of human TRBV9
WO2023146437A1 (en) * 2022-01-31 2023-08-03 Joint Stock Company «Biocad» Pharmaceutical composition of anti-trbv9 antibody and use thereof
RU2826886C1 (ru) * 2022-01-31 2024-09-17 Акционерное общество "БИОКАД" Фармацевтическая композиция анти-trbv9 антитела и ее применение
MA66989A1 (fr) * 2022-01-31 2025-07-31 Joint Stock Company "Biocad" Composition pharmaceutique d'anticorps anti-trbv9 et son utilisation
RU2860961C2 (ru) * 2023-04-21 2026-04-27 Акционерное общество "БИОКАД" Способ лечения заболевания или нарушения, опосредованного т-лимфоцитами, несущими в составе т-клеточного рецептора сегмент trbv9
RU2855818C2 (ru) * 2023-08-17 2026-02-03 Акционерное общество "БИОКАД" Способ лечения заболевания или нарушения, опосредованного т-лимфоцитами, несущими в составе т-клеточного рецептора сегмент trbv9

Also Published As

Publication number Publication date
WO2020091635A3 (ru) 2020-10-22
JP2022532274A (ja) 2022-07-14
CO2021008218A2 (es) 2021-07-30
EP3907239A2 (en) 2021-11-10
PE20220217A1 (es) 2022-02-02
CA3124813A1 (en) 2020-07-02
JOP20210169B1 (ar) 2025-10-01
PH12021551532A1 (en) 2022-02-28
US20220112286A1 (en) 2022-04-14
ZA202104357B (en) 2022-09-28
CN114144432A (zh) 2022-03-04
MA53689A1 (fr) 2022-06-30
WO2020139175A3 (ru) 2020-10-29
WO2020091635A2 (ru) 2020-05-07
ECSP21046333A (es) 2021-07-30
CA3127767A1 (en) 2020-05-07
CN113646333A (zh) 2021-11-12
PH12021551775A1 (en) 2022-05-23
KR102788029B1 (ko) 2025-03-31
US12227572B2 (en) 2025-02-18
MY205967A (en) 2024-11-21
JOP20210169A1 (ar) 2023-01-30
EA202191813A1 (ru) 2021-10-07
SG11202106975VA (en) 2021-07-29
IL284370A (en) 2021-08-31
KR20210119404A (ko) 2021-10-05
BR112021012555A2 (pt) 2021-09-14
CR20210354A (es) 2021-12-20
CO2021009689A2 (es) 2021-08-09
TW202039574A (zh) 2020-11-01
WO2020139175A2 (ru) 2020-07-02
CN113646333B (zh) 2025-04-08
MX2021007719A (es) 2022-03-25
AU2020204492A1 (en) 2021-08-12
CL2021001705A1 (es) 2022-01-28
EP3907239A4 (en) 2022-10-05
AR117734A1 (es) 2021-08-25
KR20220131489A (ko) 2022-09-28
MA53689B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
US12514923B2 (en) Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9
US12297269B2 (en) Monoclonal antibodies that bind specifically to human TRBV9
CN113474362A (zh) 对cd44特异性的抗体
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека
TWI914298B (zh) 特異性結合至人類Ｔ細胞受體之ＴＲＢＶ-９家族之β區的單株抗體及其使用之方法
TWI917314B (zh) 針對人類ＴＣＲ ＴＲＢＶ９第９家族之β鏈區的人類化抗體及其使用方法
OA20246A (en) Monoclonal antibodies against the beta chain region of human TRBV9.
OA20245A (en) Monoclonal antibodies that bind specifically to human TRBV9.
EA041932B1 (ru) Моноклональные антитела, которые специфически связываются с участком бета цепи семейства trbv-9 т-клеточного рецептора человека, и способы их применения
HK40039968A (en) Monoclonal antibodies and methods for using same
EA041880B1 (ru) Моноклональные антитела и способы их применения
HK40039968B (zh) 单克隆抗体及其使用方法

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20210409